• Cybin outlined two proprietary clinical programs, HLP003 and HLP004, targeting major depressive disorder and generalized anxiety disorder, citing positive Phase 2 safety and efficacy results.
• HLP003 has FDA Breakthrough Therapy Designation and is in Phase 3 studies for adjunctive treatment of major depressive disorder.
• The company expects topline data from the Phase 3 APPROACH study for HLP003 in Q4 2026.
• For HLP003 Phase 2 results in major depressive disorder, Cybin reported a mean 23-point reduction in MADRS scores from baseline at 12 months following two 16 mg doses.
• Cybin said it has filed over 350 patents, with more than 100 granted, providing patent protection until at least 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.